Sonka J, Marek J, Svacina S, Sucharda P, Stĕpán J
IIIrd Dept. of Internal Medicine, 1st Medical Faculty, Charles University, Prague, Czech Republic.
Sb Lek. 1995;96(4):299-301.
The effect of dexfenfluramine, the new serotoninergic appetite suppressor, was tested in 20 women. The drug was administered 3 months, 15 mg twice a day. A selected reduction of carbohydrate and of fat intake was observed. The body weight decreased mainly due to fat loss in the abdominal region. An important decrease of blood lipids was recorded, while insulinemia and OGTT remained unchanged. Serum alkaline phosphatase increased and ALT decreased. Other liver tests did not change. During the treatment the level of cortisol, TSH, T3 and 17-ketosteroids were not affected. T4 decreased and GH increased. These metabolic and hormonal effects were discussed. The treatment with dexfenfluramine was well tolerated and was found to have several favourable effects.
对20名女性进行了新型血清素能食欲抑制剂右芬氟拉明效果的测试。该药物服用3个月，每日两次，每次15毫克。观察到碳水化合物和脂肪摄入量有特定程度的减少。体重下降主要归因于腹部脂肪的减少。记录到血脂显著降低，而胰岛素血症和口服葡萄糖耐量试验保持不变。血清碱性磷酸酶升高，谷丙转氨酶降低。其他肝功能检查未发生变化。治疗期间，皮质醇、促甲状腺激素、T3和17 - 酮类固醇水平未受影响。T4降低，生长激素升高。对这些代谢和激素效应进行了讨论。右芬氟拉明治疗耐受性良好，且发现有若干有益效果。
